111in zevalin
mAbexperimentalImaging agent
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2003 (NCT00089284)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD20Radiodepletion
MS4A1 radiodepletion
Chemistry & pharmacology
- Multi-specific
- No
- Imaging
- 111-indium
Oral
No
Parenteral
No
Topical
No
Also known as
- 111in zevalin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00477815 | Phase 1 | May 1, 2005 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00089284 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2003 | Northwestern University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2005 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2005 |
| Northwestern University | Academic/Hospital | 1 | 1 | 1 | 2003 |
3 organizations
Page 1 / 1